



Minos Biosciences is bringing a new dimension to single-cell analysis & raises a Seed Investment round with Elaia



April 15th, 2021, Paris – Minos Biosciences, a deeptech spin-off of ESPCI Paris – PSL, announces a €1.5M Seed Round led by Elaia through the PSL Innovation Fund.

Minos Biosciences is developing a breakthrough solution, allowing direct mapping of microscopic observation of each individual cell onto its genomic, epigenomic and transcriptomic information, for tens of thousands of cells simultaneously. Minos Biosciences ambition is to become a leading solution provider in the fast-growing single-cell analysis market for life sciences and clinical research as well as diagnostics. Minos' disruptive innovation offers a new dimension and depth of interpretation of the information that can be derived from single-cell analysis, thereby helping to accelerate discovery in critical areas of biology and medicine.

A BREAKTHROUGH TECHNOLOGY

Single-cell analysis allows scientists to study tissues at unprecedented resolution, and is essential to better understand complex and heterogeneous biological systems. But important technical hurdles are yet to be solved to unlock the full potential of single-cell biology, and that is exactly where Minos' advantages lies. Minos Biosciences has developed a combination of innovative technologies, using state-of-the-art microfluidics, molecular biology, image analysis and bioinformatics, that will overcome major obstacles for life science and clinical research. By allowing the functional characteristics of individual cells, obtained by microscopy, to be cross-referenced with DNA/RNA sequencing for each cell in a sample containing tens of thousands of cells, the cutting-edge solution developed by Minos Biosciences will bring a new dimension to the understanding of the complex functioning of healthy and diseased tissues or organisms, opening up unique perspectives for the development of more effective and personalised treatments.

A FAST-GROWING MARKET

The single-cell genomic analysis market has been growing at a CAGR of 20% since 2014 and the market is anticipated to reach \$6B in valuation by the end of 2025. This growth has also translated to M&A transactions and fundraises. Fuelled by the pharmaceutical industry's ever-growing need for innovation accentuated by the Covid-19 crisis, and the increasing focus on personalized medicine, key players are doubling their revenues yearly and are confirming both the need of the market for single cell analysis technologies and its growth potential.

ACADEMIC EXCELLENCE & INTERDISCIPLINARITY AT THE HEART OF THE PROJECT

Based on 9 years of research and development, Minos Biosciences emerged from the interdisciplinary and highly innovative environment that characterize the ESPCI Paris – PSL engineering school and the research campus of Université PSL in Paris, and more specifically from work performed by Hubert Geisler and Gaël Blivet, two PhD students in the laboratories of the internationally renowned researchers Patrick Tabeling and Andrew Griffiths who are already behind several successful ESPCI Paris spin-offs. Minos was co-

founded by a team of leading scientists with highly complementary expertise, including Andrew Griffiths and Patrick Tabeling, Aurélien de Reyniès (Ligue Contre le Cancer), Jérôme Cros (APHP, Beaujon Hospital) and Yannick Rondelez (CNRS / ESPCI Paris).

“Elaiia PSL Innovation Fund’s investment in Minos is the archetype of our practice of investment in spin-offs from research laboratories. From our first meeting with the scientific inventors Andrew and Patrick, we had intuition of the potential of their single cell analysis which can couple phenotype (imaging of cells) to omic analysis at high throughput. We were convinced by the differentiation of their patents. We then organized a market study especially in the USA market, which confirmed the huge opportunity. This enabled us to structure the team around Hubert, Gaël, and the hiring of Pierre Le Ber, and experienced entrepreneurs in the strategic committee. We are very proud that Minos has validated its first milestones, and is reaching a new step in its development, with a clear opportunity of positioning in a fast growing market” says Anne-Sophie Carrese, partner at Elaiia.

A CLEAR ROADMAP, SUPPORTED BY STRONG ENTREPRENEURIAL EXPERTISE

Founded in January 2020, Minos Biosciences has already reached a number of key technological and business milestones, including exclusive licenses secured from PSL University for 4 patents, two of which constitute the core of its IP and the other two relating to essential technological building blocks.

Another key milestone for Minos Biosciences in January 2021 was the appointment of Pierre Le Ber as Chief Operating Officer (COO) of the company. During his 30-year career, Pierre has held various scientific and operational leadership positions in the pharma and biotech industries as well as in academia. Before joining Minos, Pierre has been for 8 years the director and scientific coordinator of the “France Génomique” national infrastructure and brings to Minos his tremendous insight into genomic technologies and their applications.

“The seed round of €1.5M raised by Minos Biosciences, led by Elaiia through the PSL Innovation Fund, will allow Minos to considerably accelerate its development by reinforcing its R&D team, developing its first prototype and validating its first applications in close collaboration with top academic laboratories & institutions. It will also allow Minos to prepare the industrial prototyping phase of its solution” says Pierre Le Ber, COO of Minos Biosciences.

ABOUT MINOS BIOSCIENCES

Minos Biosciences is an early-stage deeptech start-up, spun-off from the Ecole Supérieure de Physique et Chimie Industrielles de Paris (ESPCI Paris - PSL) and incubated at PC’up Boost, the ESPCI Paris - PSL incubator at the Institut Pierre-Gilles de Gennes (IPGG). Minos is developing a unique and revolutionary technology for single-cell analysis at very high-throughput, combining state-of-the-art microfluidics, molecular biology, image analysis and bioinformatics and allowing a direct coupling of phenotypic and multi-omic data at single-cell resolution.

ABOUT ELAIA PARTNERS

Elaiia is a European top-tier VC firm with a strong tech DNA. They back tech disruptors with global ambition from early stage to growth development. For the past 18 years, our commitment has been to deliver high performance with values.

We are proud to have been an active partner in over 100 startups including success stories such as Criteo (Nasdaq), Orchestra Networks (acquired by Tibco), Teads (acquired by Altice), Mirakl (valued \$1.5B in Series D) and Shift Technology.

Learn more <http://www.elaiia.com> • [@Elaiia Partners](#)

PRESS CONTACT

Pierre Le Ber - Minos Biosciences - pierre.leber@minosbiosciences.com

Louisa Mesnard - Elaiia - lmesnard@elaiia.com